Rogers v. BAXTER INTERNATIONAL INC.

710 F. Supp. 2d 722, 48 Employee Benefits Cas. (BNA) 2857, 2010 U.S. Dist. LEXIS 43586, 2010 WL 1780349
CourtDistrict Court, N.D. Illinois
DecidedMay 3, 2010
Docket04 C 6476
StatusPublished
Cited by13 cases

This text of 710 F. Supp. 2d 722 (Rogers v. BAXTER INTERNATIONAL INC.) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Rogers v. BAXTER INTERNATIONAL INC., 710 F. Supp. 2d 722, 48 Employee Benefits Cas. (BNA) 2857, 2010 U.S. Dist. LEXIS 43586, 2010 WL 1780349 (N.D. Ill. 2010).

Opinion

MEMORANDUM OPINION AND ORDER

JOAN B. GOTTSCHALL, District Judge.

Plaintiff David E. Rogers represents a class of participants in and beneficiaries of the Baxter International Inc. and Subsidiaries Incentive Investment Plan (the “Plan”). Rogers brings suit against Baxter International Inc. (“Baxter”) and several related defendants for alleged breaches of fiduciary duties owed to the class under the Employee Retirement Income Security Act of 1974 (“ERISA”), Pub.L. No. 93-406, 88 Stat. 829 (codified as amended in scattered sections of 5 U.S.C., 18 U.S.C., 26 U.S.C., 29 U.S.C., and 42 U.S.C.). This case is presently before the court on defendants’ motion for summary judgment and Rogers’s motion for partial summary judgment.

I. Facts 1

A. Background 2

Since 1985, Baxter, a seller of pharmaceuticals and other healthcare-related products, has maintained the Plan for its employees’ 401 (k) contributions. (See Defs.’ Resp. ¶ 1; see also Pl.’s Resp. ¶ 3.) At the time of the events in question, the 1997 version of the Plan was in effect. (Defs.’ Resp. ¶2.) Baxter was the Plan’s sponsor and had responsibility for investment matters relating to the Plan. (Pl.’s Resp. ¶ 3; see also Defs.’ Resp. ¶ 6.) Two Baxter committees, the defendant Investment Committee and the defendant Administrative Committee, were responsible for administering and managing the Plan, *726 and therefore were fiduciaries. (Defs.’ Resp. ¶¶ 3, 5.) Defendant Brian Anderson was Baxter’s Chief Financial Officer, a member of the Administrative and Investment Committees, and a Plan fiduciary at all relevant times. (Id. ¶ 5; PL’s Resp. ¶¶ 3-4.) Defendant Harry M. Jansen Kraemer, Jr. was Baxter’s Chief Executive Officer and Chairman of the Board of Directors at relevant times.

Plaintiff Rogers is a participant in the Plan who elected to invest a portion of his contributions to the Plan in the Baxter Common Stock Fund. (PL’s Resp. ¶ 3.) He represents a class of investors who held stock in Baxter through their individual Plan accounts at any time between January 1, 2001 and the present. (Id. ¶ 2; see also Doc. Nos. 78-79.)

B. The Plan

The Plan was a defined-contribution plan, meaning each Plan participant had an individual account, the benefits of which were based solely on the amount contributed thereto. (PL’s Resp. ¶ 7.) Plan participants could make tax-deferred contributions to their respective accounts under § 401(k) of the Internal Revenue Code, 26 U.S.C. § 401(k), and Baxter matched those contributions up to a certain limit. (Id. ¶ 8.)

In addition to determining how much was invested in their individual accounts, Plan participants directed what investments to make. (Defs.’ Resp. ¶¶ 11-13.) The Investment Committee offered Plan participants the opportunity to invest in seven different investment “funds,” including five diversified funds, and offered a self-managed brokerage window through which Plan participants could invest in several thousand mutual funds. (See PL’s Resp. ¶ 42; see also Defs.’ Ex. D-3, at 8-9.) Each fund was described in a Summary Plan Description (“SPD”) 3 provided to Plan participants, see PL’s Resp. ¶ 42, Defs.’ Ex. D-5, at 12, and Plan participants could obtain more detailed information regarding any fund on request. (PL’s Resp. ¶¶ 46, 54; see also Defs.’ Resp. Ex. D ¶¶ 18, 27; Defs.’ Ex. D-6, at BAXR 001977.) Plan participants would then direct the investment of their account assets in the funds of their choice. (See PL’s Resp. ¶¶ 57-63.)

During the relevant period, the Baxter Common Stock Fund was among the seven funds that the Investment Committee selected to be investment options for participants in the Plan. (Defs.’ Resp. ¶ 21; see also PL’s Resp. ¶ 16.) SPDs provided Plan participants with information regarding voting and tender rights in Baxter common stock, and regarding confidentiality procedures related to transactions in Baxter common stock. (Defs.’ Resp. Ex. D-3, at 13-14.) The Plan also had procedures to ensure that participants could exercise voting, tender, and similar rights in a confidential manner. (PL’s Resp. ¶ 68.)

C. Baxter’s Commitments and Stock Price Decline

Each year, Baxter issued periodic financial guidance, which it termed “commitments,” to the public. (Defs.’ Add’l Resp. ¶¶ 4, 26.) These “commitments” forecast-ed financial information not just for Baxter generally, but also for each of Baxter’s specific divisions. (Id. ¶25.) In October 2001, Baxter announced its commitments for 2002, which included commitments to “[ajccelerate sales growth to the low- *727 teens” and “[g]row earnings-per-share in the mid-teens.” (Id. ¶ 34; see also Pl.’s Resp. ¶ 20.) As of its October 2001 announcement, Baxter had met its annual earnings and cash flow commitments for the seven previous years. (PL’s Resp. ¶ 21.)

In Baxter’s Annual Report to shareholders, Kraemer indicated that the commitment, if realized, would be “our highest sales-growth rate in almost 20 years.” (PL’s Resp. Ex. 66, at 6.) While the commitments for 2002 exceeded Baxter’s historical sales growth rate, Defs.’ Add’l Resp. ¶¶ 45-46, they were consistent with internally projected sales growth. (PL’s Resp. Ex. 52, at 10.) Internally, Baxter noted that its commitments were “reasonable and realistic.” (Id. at 20.) Also internally, Baxter set a goal of increasing the value of Baxter common stock from $62.81 per share to over $200 per share. (See PL’s Resp. Ex. 45, at 8.)

Baxter’s growth continued through 2001, and on January 24, 2002, Baxter announced that it had met its commitments for the previous year, its eighth consecutive such year. (PL’s Resp. ¶ 22.) On the same day, however, Kraemer held a conference call with analysts in which he revised downward the expected growth of Baxter’s renal and bioscience divisions. (See PL’s Resp. Ex. 22, at 18; see also Defs.’ Add’l Resp. ¶ 63.) Throughout the first quarter of 2002, Baxter’s renal division internally reported sales, sales growth, income, and cash flow that were short of previous estimates. (Defs.’ Add’l Resp. ¶¶ 65, 67.)

On July 18, 2002, Baxter released its second quarter earnings results; in a conference call with analysts that day, Kraemer called Baxter’s quarterly sales increase of eight percent “clearly disappointing.” (Id. ¶ 68.) The specific reason for the lagging increase in sales appears to have been the renal division, which contemporaneously announced that its sales growth would be revised downward for the second time that year. (Id. ¶ 69.) In the same conference call, Kraemer reaffirmed that he expected that Baxter would meet its 2002 commitments. (Id. ¶¶ 70-71; see also PL’s Resp.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Untitled Case
N.D. Illinois, 2026
Dale v. NFP Corp.
N.D. Illinois, 2023
Andrew Albert v. Oshkosh Corporation
47 F.4th 570 (Seventh Circuit, 2022)
Albert v. Oshkosh Corporation
E.D. Wisconsin, 2021
Chesemore v. Alliance Holdings, Inc.
886 F. Supp. 2d 1007 (W.D. Wisconsin, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
710 F. Supp. 2d 722, 48 Employee Benefits Cas. (BNA) 2857, 2010 U.S. Dist. LEXIS 43586, 2010 WL 1780349, Counsel Stack Legal Research, https://law.counselstack.com/opinion/rogers-v-baxter-international-inc-ilnd-2010.